PT Diastika Biotekindo Tbk (IDX:CHEK)

IDX:CHEK Income Statement

Financials in millions IDR. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Revenue	154,792	129,098	117,468
Revenue Growth (YoY)	19.90%	9.90%	-
Cost of Revenue	96,746	83,141	76,290
Gross Profit	58,046	45,956	41,178
Selling, General & Admin	38,167	33,563	27,836
Other Operating Expenses	515.71	277.27	120.65
Operating Expenses	38,683	33,840	27,957
Operating Income	19,363	12,117	13,221
Interest Expense	-258.55	-32.73	-0.15
Interest & Investment Income	183.57	260.67	331.56
Currency Exchange Gain (Loss)	261.69	-514.78	626.84
Other Non Operating Income (Expenses)	-268.98	5,542	-47.41
EBT Excluding Unusual Items	19,281	17,371	14,132
Gain (Loss) on Sale of Assets	5.59	169.2	2,627
Pretax Income	19,287	17,540	16,759
Income Tax Expense	4,112	3,950	3,723
Net Income	15,175	13,591	13,035
Net Income to Common	15,175	13,591	13,035
Net Income Growth	11.65%	4.26%	-
Shares Outstanding (Basic)	5,023	5,023	5,023
Shares Outstanding (Diluted)	5,023	5,023	5,023
EPS (Basic)	3.02	2.71	2.60
EPS (Diluted)	3.02	2.71	2.60
EPS Growth	11.65%	4.26%	-
Free Cash Flow	-1,934	3,330	534.23
Free Cash Flow Per Share	-0.39	0.66	0.11
Gross Margin	37.50%	35.60%	35.05%
Operating Margin	12.51%	9.39%	11.25%
Profit Margin	9.80%	10.53%	11.10%
Free Cash Flow Margin	-1.25%	2.58%	0.46%
EBITDA	26,972	17,460	18,775
EBITDA Margin	17.42%	13.53%	15.98%
D&A For EBITDA	7,609	5,343	5,553
EBIT	19,363	12,117	13,221
EBIT Margin	12.51%	9.39%	11.25%
Effective Tax Rate	21.32%	22.52%	22.22%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.